Abstract
IntroductionOsteopenia is commonly seen in people over age 50 that have lower than average bone density but do not have osteoporosis. The diagnostic difference between osteopenia and osteoporosis is the measure of bone mineral density. Tenofovir is an antiviral drug that is approved for the treatment of chronic hepatitis B and to prevent and treat Human Immunodeficiency Viruses (HIV) infection. It may cause to reduce Bone Mineral Density (BMD) in some patients. ObjectiveThis study aimed Comparing the Frequency of Osteoporosis and Osteopenia in Chronic Hepatitis B Patients with and without Tenofovir treatment. Materials and methodsThis study was conducted in 2018 as a cohort study on 209 patients with chronic hepatitis B, who referred to Imam Khomeini Hospital and the Gastroenterologist's Office in Ahvaz. Patients evaluated in two groups including Tenofovir group (receiving Tenofovir for more than 12 months) (n = 139) and control group (candidates for Tenofovir and had no history of taking Tenofovir or other anti-inflammatory drugs) (n = 70). BMD was evaluated in all patients by Dual-Energy X-ray Absorptiometry (DEXA) scan and compared in the two groups. ResultsThe frequency percentage of patients with osteopenia and osteoporosis in the Tenofovir group (60.43%) was significantly more than that of the control group (21.43%) (P < 0.05). Among Tenofovir group, 51.02% of males and 42.22% of females had osteopenia. Also, 14.28% of males and 15.56% of females had osteoporosis. In the patients who had consumed more time, incidence of osteoporosis and osteopenia were reported more often (P > 0.05). Among patients with osteopenia, 85.71% of the patients in the hip region and 44.44% of them in the lumber area had decreased bone density. Also, osteoporosis was more reported in hip (90.48%), lumbar (90.48%) and femoral neck (80.95%) respectively. ConclusionA significant reduction in bone density was observed in patients with chronic hepatitis B receiving Tenofovir for more than 12 months in comparison with the control group. Also, the patients who had been taking Tenofovir in longer time, osteoporosis and osteopenia were more reported.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
